O Shaughnessy Asset Management LLC Sells 254,639 Shares of Pfizer Inc. (NYSE:PFE)
O Shaughnessy Asset Management LLC has reduced its stake in Pfizer Inc. (NYSE:PFE) by 55.6%, selling 254,639 shares during the 4th quarter, leaving it with 203,518 shares valued at $5.4 million. Other institutional investors also increased their holdings in Pfizer. Analysts have mixed ratings on the stock, with price targets ranging from $29 to $32. Pfizer's recent earnings report showed a profit of $0.63 per share, exceeding expectations, with revenue of $17.76 billion, a 24.7% increase year-over-year.
O Shaughnessy Asset Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 55.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 203,518 shares of the biopharmaceutical company's stock after selling 254,639 shares during the period. O Shaughnessy Asset Management LLC's holdings in Pfizer were worth $5,399,000 at the end of the most recent quarter.
- 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
Other institutional investors also recently modified their holdings of the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the 4th quarter valued at $32,000. Institutional investors own 68.36% of the company's stock.
Analysts Set New Price Targets
PFE has been the topic of a number of recent analyst reports. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $31.92.
- Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
View Our Latest Stock Analysis on PFE
Insiders Place Their Bets
In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company's stock.
Pfizer Trading Down 3.2 %
- These Stocks Missed on Earnings, But Will Rebound Next Quarter
NYSE PFE opened at $24.53 on Wednesday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The business's fifty day moving average is $26.00 and its 200 day moving average is $26.84. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $139.09 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the business posted $0.10 earnings per share. The business's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Company Profile
(Free Report)Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
- Five stocks we like better than Pfizer
- Biggest Stock Losers - Today’s Biggest Percentage Decliners
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Top Biotech Stocks: Exploring Innovation Opportunities
- Amazon Falls Back to a Key Support Line: Here's How to Play It
- What Are Treasury Bonds?
- Buffett Trims Equities, But Still Keeps Buying This Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Pfizer Right Now?
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
